ArticleEuropean journal of nuclear medicine and molecular imaging2017
Treatment response evaluation with
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brown tumors in nuclear medicine: a systematic review.Annals of nuclear medicine · 2023Pooled it
- Role of Composite Measurable Residual Disease Assessment with PET-CT and flow cytometry in Multiple Myeloma patients undergoing Autologous Transplant.Blood cell therapy · 2025Article
- Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.Journal of bone oncology · 2025Review
- Age-related sensitivity deterioration evaluation of positron emission tomography utilizing cross-calibration factor measurement data.Radiological physics and technology · 2025Article
- Dynamic FDG PET/CT imaging: quantitative assessment, advantages and application in the diagnosis of malignant solid tumors.Frontiers in oncology · 2025Review
- Head-to-Head Comparison between FDG andDiagnostics (Basel, Switzerland) · 2023Review
- Comparison of [Molecular imaging and biology · 2022Article
- DynamicRadiology. Imaging cancer · 2022Article
- Molecular Imaging in Multiple Myeloma-Novel PET Radiotracers Improve Patient Management and Guide Therapy.Frontiers in nuclear medicine · 2022Review
- Role of FDG PET in the staging of multiple myeloma.Skeletal radiology · 2022Review
- Quantitative, DynamicDiagnostics (Basel, Switzerland) · 2021Article
- Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting.Diagnostics (Basel, Switzerland) · 2021Review
- Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives.European journal of nuclear medicine and molecular imaging · 2021Review
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Multiple Myeloma Associated Bone Disease.Cancers · 2020Review
- CanCancers · 2020Article
- Article
- Prognostic significance ofAmerican journal of nuclear medicine and molecular imaging · 2020Article
- The Peripheral Blood Transcriptome Is Correlated With PET Measures of Lung Inflammation During Successful Tuberculosis Treatment.Frontiers in immunology · 2020Article
- Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.Molecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of this study was to assess the combined use of the radiotracers PATIENTS AND
methodsThirty-four patients with primary, previously untreated MM scheduled for treatment with HDT followed by ASCT were enrolled in the study. All patients underwent PET/CT scanning with
resultsAn analysis was possible in 29 patients: three with clinical complete response (CR) and 26 with non-CR (13 patients near complete response-nCR, four patients very good partial response-VGPR, nine patients partial response-PR). After treatment,
conclusionF-FDG PET/CT demonstrated a sensitivity of 57.7 % and a specificity of 100 % in treatment response evaluation of MM. Despite its limited sensitivity, the performance of
Indexed as
Identifiers
27573638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.